(firstQuint)A Study of the Long-term Safety of Sativex Use.

 Subjects who had previously participated in a placebo controlled GW clinical study were screened and if eligible began dosing with GW-1000-02.

 Subjects were reviewed for tolerability and evidence of clinical benefit at weeks two and four and then every eight weeks.

 Subjects self-titrated to symptom resolution or maximum tolerated/allowable dose of 130 mg THC and 120 mg CBD.

.

 A Study of the Long-term Safety of Sativex Use@highlight

Subjects who had previously received GW-1000-02 in a GW study who opted to continue using it in the long-term were monitored for ongoing tolerability and evidence of clinical benefit.

